Thermopylae buys 38,000 AbCellera shares

Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., bought 38,000 common shares in an open-market purchase at a weighted-average price of $3.44 per share, with individual trade prices ranging from $3.42 to $3.45.

Rhea-AI Filing Summary

Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., bought 38,000 common shares in an open-market purchase at a weighted-average price of $3.44 per share, with individual trade prices ranging from $3.42 to $3.45.

After this transaction, Thermopylae Holdings directly owns 56,134,097 AbCellera common shares, reinforcing its already significant stake in the company.

Insider Trade Summary

Net Buyer: 38,000 shares

Net Buy 1 txn

Insider Thermopylae Holdings Ltd.

Role 10% Owner

Bought 38,000 shs ($131K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	38,000	$3.44	$131K

Holdings After Transaction: Common Shares — 56,134,097 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.42 to $3.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Thermopylae Holdings report for ABCL?

Thermopylae Holdings Ltd. reported buying 38,000 AbCellera common shares in an open-market transaction. The weighted-average purchase price was $3.44 per share, with trades executed between $3.42 and $3.45 per share.

What price did Thermopylae Holdings pay for AbCellera (ABCL) shares?

Thermopylae Holdings paid a weighted-average price of $3.44 per AbCellera common share. The Form 4 notes that individual trades occurred at prices ranging from $3.42 to $3.45, reflecting multiple executions within that narrow band.

How many AbCellera (ABCL) shares does Thermopylae Holdings own after this trade?

Following the reported purchase, Thermopylae Holdings directly owns 56,134,097 AbCellera common shares. This updated ownership figure on the Form 4 highlights the entity’s continued status as a significant, over-10% shareholder in the company.

Was the Thermopylae Holdings ABCL transaction a buy or sell?

The transaction was a buy. Thermopylae Holdings executed an open-market purchase of 38,000 AbCellera common shares, reported under transaction code “P,” which indicates a purchase in the open market or a private transaction under SEC rules.

What does the price range footnote mean in the ABCL Form 4?

The footnote explains the reported price is a weighted-average across multiple trades. AbCellera shares were acquired in separate transactions between $3.42 and $3.45, and Thermopylae Holdings offers to provide exact trade breakdowns upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 02:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thermopylae Holdings Ltd.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER A1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/27/2026		P	V	38,000	A	$3.44(1)	56,134,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.42 to $3.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Remarks:

	Tryn Stimart, attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.